Literature DB >> 22764569

Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells.

K Togami1, S Chono, K Morimoto.   

Abstract

We have shown that clarithromycin (CAM), a macrolide antibiotic, more highly distributes from plasma to lung epithelium lining fluid (ELF), the infection site of pathogens, than azithromycin (AZM) and telithromycin (TEL). Transporter(s) expressed on lung epithelial cells may contribute to the distribution of the compiunds to the ELF. However, distribution mechanisms are not well known. In this study, their transport characteristics in Calu-3 cell monolayers as model lung epithelial cells were examined. The basolateral-to-apical transport of CAM through Calu-3 cell monolayers was greater than that of AZM and TEL. Although verapamil and cyclosporine A as MDR1 substrates completely inhibited the basolateral-to-apical transport, probenecid as MRP1 inhibitor did not show an effect. These results suggest that the antibiotics are transported from plasma to ELF by MDR1 of lung epithelial cells. In addition, their affinity and binding rate to MDR1 was examined by ATP activity assay. The affinity and binding rate of CAM was greater than those of AZM and TEL. These corresponded with the distributions from plasma to ELF as described above. The present study suggests that the more highly distribution of CAM from plasma to ELF is due to the high affinity and binding rate to MDR1 of lung epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22764569

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  7 in total

1.  To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.

Authors:  Sieto Bosgra; Maria L H Vlaming; Wouter H J Vaes
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

Review 2.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

Review 3.  Predictive Value of Microdose Pharmacokinetics.

Authors:  Merel van Nuland; Hilde Rosing; Alwin D R Huitema; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2019-10       Impact factor: 6.447

4.  Comparative plasma exposure and lung distribution of two human use commercial azithromycin formulations assessed in murine model: a preclinical study.

Authors:  Virginia Rivulgo; Mónica Sparo; Mónica Ceci; Elida Fumuso; Alejandra Confalonieri; Gastón Delpech; Sergio F Sánchez Bruni
Journal:  Biomed Res Int       Date:  2013-08-29       Impact factor: 3.411

5.  In Vitro-In Silico Modeling of Caffeine and Diclofenac Permeation in Static and Fluidic Systems with a 16HBE Lung Cell Barrier.

Authors:  Lukas Kovar; Lena Wien; Dominik Selzer; Yvonne Kohl; Robert Bals; Thorsten Lehr
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-18

6.  Development of a Multicompartment Permeability-Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs.

Authors:  L Gaohua; J Wedagedera; B G Small; L Almond; K Romero; D Hermann; D Hanna; M Jamei; I Gardner
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-10-09

Review 7.  Study of the structural, chemical descriptors and optoelectronic properties of the drugs Hydroxychloroquine and Azithromycin.

Authors:  G W Ejuh; C Fonkem; Y Tadjouteu Assatse; R A Yossa Kamsi; Tchangnwa Nya; L P Ndukum; J M B Ndjaka
Journal:  Heliyon       Date:  2020-08-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.